The inhibitory and synergistic role of liponanocortisone on monocytes, lymphocytes, and platelets in male rats with arthritis

Nanotechnology in the treatment of diseases is considered one of the prominent techniques for obtaining safe and effective medicines and treatments at the same time. The aim of the research is to know the synergistic therapeutic effect of liponanocortisone in improving arthritis in rats. Fifteen rats were used in this experiment, divided into three groups (five rats per group), the first group was injected with Normal Saline (as a control group), the second group induced arthritis, it was injected with FIA for a week, the third group, after a week elapsed for the development of arthritis, this was injected The group took liponanocortisone for a week as well. The results of the current study showed significant changes in the percentage of lymphocytes, monocytes and platelets in the third group, compared with the control group and the arthritis group. This study revealed that patients with joint pain who develop arthritis show a change in cellular immune parameters that appear in the periphery, starting with a decrease in lymphocytes with an increase in the percentage of monocytes and platelets, meaning that there is a synergistic association between monocytes and Platelets leading to arthritis. The current study also indicated the efficiency of the therapeutic compound in inhibiting this association between monocytes and platelets by disabling this association and raising the percentage of lymphocytes and increasing their association with platelets to act as an anti-arthritis.